- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01692132
A Post Marketing Surveillance Study on the Safety and Effectiveness of Prucalopride in the Treatment of Chronic Constipation
November 30, 2015 updated by: Janssen Pharmaceutica
A Study on the Safety and Effectiveness of Prucalopride in the Treatment of Chronic Constipation
The purpose of this study is to determine the safety and effectiveness of prucalopride in the treatment of Filipino patients with chronic constipation whom prior laxatives fail to provide adequate relief.
Study Overview
Detailed Description
This is a 12-week open label (all people know the identity of the intervention), multi-center, prospective (the patients are identified and then followed forward in time for the outcome of the study) observational study assessing the safety and effectiveness of prucalopride among Filipino patients with chronic constipation.
Chronic constipation is a condition in which bowel movements are infrequent or incomplete for a prolonged time.
The use of prucalopride should be used in accordance with the approved product label and will follow the normal medical practice of the investigators.
Patients should take 2 mg prucalopride tablet orally once daily.
For elderly patients (>65 years old), patients with renal impairment not requiring dialysis or patients with severe hepatic impairment, 1mg prucalopride once daily should be given.
Patients will be asked to fill-up a patient diary daily for 12-weeks to monitor the bowel movement during the study period.
All adverse events and concomitant medications taken by the patients during the study will be documented accordingly.
Patients will be monitored during the 12-week period of observation while the patients are in prucalopride treatment.
Study Type
Observational
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Makati City, Philippines
-
Manila, Philippines
-
Marikina City, Philippines
-
Muntinlupa, Philippines
-
Quezon City, Philippines
-
San Juan, Philippines
-
Taguig, Philippines
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Filipino patients with chronic constipation
Description
Inclusion Criteria:
- Diagnosis of chronic constipation by history and physical examination, including rectal exam
- History of chronic constipation not satisfied with laxatives
- Patient reports, on average, 2 or fewer spontaneous bowel movements (SBMs) per week and 1 or more of the following for the last three months: very hard (little balls) and/or hard stools in more than 25% of bowel movements (BMs); sensation of incomplete evacuation in more than 25% of BMs; straining at defecation in more than 25% of BMs; sensation of ano-rectal obstruction or blockade in more than 25% of BMs; a need for digital manipulation to facilitate evacuation in more than 25% of BMs
- Females of childbearing potential agree to use highly effective contraceptive methods
Exclusion Criteria:
- Renal impairment requiring dialysis
- Secondary chronic constipation and organic gastrointestinal (GI) disorders
- Intestinal perforation / obstruction due to structural or functional disorder of the gut wall, obstructive ileus, severe inflammatory condition of the intestinal tract such as Crohn's disease, ulcerative colitis, toxic megacolon / rectum
- Hypersensitive to Prucalopride or to any of its components
- Patients receiving concomitant drugs known to cause QTc prolongation
- Pregnant or lactating
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Prucalopride
|
Prucalopride 2 mg tablet/day orally for 12 weeks.
For elderly patients (>65 years old), patients with renal impairment not requiring dialysis or patients with severe hepatic impairment, 1mg prucalopride once daily should be given.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The incidence of patients discontinuing treatment due to adverse events, serious adverse events, or adverse drug reactions
Time Frame: 12 weeks
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The percentage of patients having at least 3 spontaneous complete bowel movements (SCBM) in a week after treatment with prucalopride
Time Frame: 12 weeks
|
SCBM is defined as a sense of complete evacuation of bowel without straining.
|
12 weeks
|
The change from baseline in the Patient Assessment of Constipation Symptoms (PAC-SYM) score after treatment with prucalopride
Time Frame: Baseline, 12 weeks
|
The PAC-SYM questionnaire is a 12-item survey that measures constipation symptoms and associated severity across three domains: stool symptoms, rectal symptoms, and abdominal symptoms.
Symptom items are rated on a 5-point Likert severity scale.
Item values are scored from 0 to 4, with 0 indicating absence of symptom, 1 = mild, 2 = moderate, 3 = severe, and 4 = very severe indicating the worst severity of that symptom.
|
Baseline, 12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2013
Primary Completion (ANTICIPATED)
February 1, 2014
Study Completion (ANTICIPATED)
December 1, 2014
Study Registration Dates
First Submitted
September 20, 2012
First Submitted That Met QC Criteria
September 20, 2012
First Posted (ESTIMATE)
September 25, 2012
Study Record Updates
Last Update Posted (ESTIMATE)
December 2, 2015
Last Update Submitted That Met QC Criteria
November 30, 2015
Last Verified
November 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CR017521
- PRUCOP4001 (OTHER: Janssen Pharmaceutica)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Constipation
-
Faming ZhangNot yet recruitingChronic ConstipationChina
-
usMIMA S.L.CompletedConstipation | Constipation Chronic Idiopathic | Constipation; NeurogenicSpain, United Kingdom
-
SK Life Science, Inc.CompletedChronic Constipation | Functional ConstipationUnited States
-
Cairo UniversityUnknownChronic Idiopathic Constipation | Functional ConstipationEgypt
-
AbbVieIronwood Pharmaceuticals, Inc.RecruitingFunctional Constipation (FC) | Chronic Idiopathic Constipation (CIC)United States, United Kingdom, Bulgaria, Netherlands
-
Air Force Military Medical University, ChinaRecruitingChronic ConstipationChina
-
Yokohama City UniversityRecruiting
-
International University of Health and WelfareTerminated
-
Astellas Pharma IncCompleted
-
AlbireoCompletedConstipation | Chronic ConstipationUnited States
Clinical Trials on Prucalopride
-
MovetisCompleted
-
MovetisCompletedHepatic ImpairmentRussian Federation
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...RecruitingPatient SatisfactionBangladesh
-
Universitaire Ziekenhuizen KU LeuvenUnknown
-
MovetisCompleted
-
ShireCompletedConstipationSpain, Romania, Italy, Poland, Czechia, Hungary, Slovakia, Sweden, Belgium
-
Janssen Korea, Ltd., KoreaCompletedConstipationKorea, Republic of
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...RecruitingIrritable Bowel SyndromeBangladesh